Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16–29 years

Since authorization of the Pfizer-BioNTech COVID-19 Vaccine, mRNA (Comirnaty), real-world evidence has indicated the vaccines are effective in preventing COVID-19 cases and related hospitalizations and deaths. However, increased cases of myocarditis/pericarditis have been reported in the United Stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Funk, Patrick R., Yogurtcu, Osman N., Forshee, Richard A., Anderson, Steve A., Marks, Peter W., Yang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958165/
https://www.ncbi.nlm.nih.gov/pubmed/35370016
http://dx.doi.org/10.1016/j.vaccine.2022.03.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958165/
https://www.ncbi.nlm.nih.gov/pubmed/35370016
http://dx.doi.org/10.1016/j.vaccine.2022.03.030

Ejemplares similares